Izalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical <i>EGFR</i> Mutations: A Phase Ib Study

iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical <i>EGFR</i> mutations, especially in <i>EGFR</i> exon20ins/nonclassical and <i>HER2</i> mutations.